杨宝剑,李睿,魏翔

• 1:华中科技大学同济医学院附属同济医院心脏大血管外科

摘要(Abstract)：

冠状动脉心肌桥(MB)在肥厚型心肌病(HCM)患者中的检出率显著高于普通人群。MB通过收缩期压迫隧道动脉及舒张期恢复延迟，与HCM固有的缺血机制相互叠加，可能加速心肌纤维化进程并增加不良心血管事件。然而，MB在HCM中的临床意义尚未被充分认识，相关诊疗策略仍有待进一步明确。本文从流行病学、病理生理机制、诊断评估及治疗策略4个方面综述该领域的研究进展，以期为临床实践提供参考。

关键词(KeyWords)： 肥厚型心肌病;冠状动脉心肌桥;心肌缺血;心肌纤维化;室间隔切除术

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 杨宝剑,李睿,魏翔

DOI: 10.13201/j.issn.1001-1439.2026.10.013

参考文献(References)：

• [1] Maron BJ.Clinical course and management of hypertrophic cardiomyopathy[J].N Engl J Med,2018,379(7):655-668.
• [2] Veselka J,Anavekar NS,Charron P.Hypertrophic obstructive cardiomyopathy[J].Lancet,2017,389(10075):1253-1267.
• [3] Maron BJ,Desai MY,Nishimura RA,et al.Diagnosis and evaluation of hypertrophic cardiomyopathy:JACC state-of-the-art review[J].J Am Coll Cardiol,2022,79(4):372-389.
• [4] Sternheim D,Power DA,Samtani R,et al.Myocardial bridging:diagnosis,functional assessment,and management:JACC state-of-the-art review[J].J Am Coll Cardiol,2021,78(22):2196-2212.
• [5] Danek BA,Kearney K,Steinberg ZL.Clinically significant myocardial bridging[J].Heart,2023,110(2):81-86.
• [6] Santucci A,Jacoangeli F,Cavallini S,et al.The myocardial bridge:incidence,diagnosis,and prognosis of a pathology of uncertain clinical significance[J].Eur Heart J Suppl,2022,24(Suppl I):I61-I67.
• [7] Hostiuc S,Negoi I,Rusu MC,et al.Myocardial bridging:a meta-analysis of prevalence[J].J Forensic Sci,2018,63(4):1176-1185.
• [8] Sorajja P,Ommen SR,Nishimura RA,et al.Myocardial bridging in adult patients with hypertrophic cardiomyopathy[J].J Am Coll Cardiol,2003,42(5):889-894.
• [9] van der Velde N,Huurman R,Yamasaki Y,et al.Frequency and significance of coronary artery disease and myocardial bridging in patients with hypertrophic cardiomyopathy[J].Am J Cardiol,2020,125(9):1404-1412.
• [10] Basso C,Thiene G,Mackey-Bojack S,et al.Myocardial bridging,a frequent component of the hypertrophic cardiomyopathy phenotype,lacks systematic association with sudden cardiac death[J].Eur Heart J,2009,30(13):1627-1634.
• [11] Bruce C,Ubhi N,McKeegan P,et al.Systematic review and meta-analysis of cardiovascular consequences of myocardial bridging in hypertrophic cardiomyopathy[J].Am J Cardiol,2023,188:110-119.
• [12] Maron MS,Olivotto I,Maron BJ,et al.The case for myocardial ischemia in hypertrophic cardiomyopathy[J].J Am Coll Cardiol,2009,54(9):866-875.
• [13] Montone RA,Camilli M,Calvieri C,et al.Coronary microvascular dysfunction across the spectrum of cardiovascular diseases:JACC state-of-the-art review[J].J Am Coll Cardiol,2021,78(13):1352-1371.
• [14] Coleman JA,Ashkir Z,Raman B,et al.Mechanisms and prognostic impact of myocardial ischaemia in hypertrophic cardiomyopathy[J].Int J Cardiovasc Imaging,2023,39(10):1979-1996.
• [15] Camici PG,Olivotto I,Rimoldi OE.The coronary circulation and blood flow in left ventricular hypertrophy[J].J Mol Cell Cardiol,2012,52(4):857-864.
• [16] Cecchi F,Olivotto I,Gistri R,et al.Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy[J].N Engl J Med,2003,349(11):1027-1035.
• [17] Raphael CE,Cooper R,Parker KH,et al.Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy:insights from wave intensity analysis and magnetic resonance[J].J Am Coll Cardiol,2016,68(15):1651-1660.
• [18] Klues HG,Schwarz ER,vom Dahl J,et al.Disturbed intracoronary hemodynamics in myocardial bridging:early normalization by intracoronary stent placement[J].Circulation,1997,96(9):2905-2913.
• [19] Schwarz ER,Klues HG,Dahl JV,et al.Functional characteristics of myocardial bridging:a combined angiographic and intracoronary Doppler flow study[J].Eur Heart J,1997,18(3):434-442.
• [20] Wu S,Wu DN,Li XL.Unveiling the masquerading of myocardial bridging in cardiovascular diseases[J].Rev Cardiovasc Med,2025,26(7):36868.
• [21] Sharzehee M,Chang Y,Song JP,et al.Hemodynamic effects of myocardial bridging in patients with hypertrophic cardiomyopathy[J].Am J Physiol Heart Circ Physiol,2019,317(6):H1282-H1291.
• [22] Brodsky SV,Roh L,Ashar K,et al.Myocardial bridging of coronary arteries:a risk factor for myocardial fibrosis?[J].Int J Cardiol,2008,124(3):391-392.
• [23] Argirò A,Parikh V,Jurcut R,et al.Hypertrophic cardiomyopathy[J].Nat Rev Dis Primers,2025,11:58.
• [24] Ommen SR,Ho CY,Asif IM,et al.2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy:a report of the American heart association/American college of cardiology joint committee on clinical practice guidelines[J].Circulation,2024,149(23):e1239-e1311.
• [25] Song CP,Wang SW,Guo XL,et al.Myocardial bridging in obstructive hypertrophic cardiomyopathy:a risk factor for myocardial fibrosis[J].BMC Med,2024,22(1):86.
• [26] Matta A,Roncalli J,Carrié D.Update review on myocardial bridging:New insights[J].Trends Cardiovasc Med,2024,34(1):10-15.
• [27] Noble J,Bourassa MG,Petitclerc R,et al.Myocardial bridging and milking effect of the left anterior descending coronary artery:normal variant or obstruction?[J].Am J Cardiol,1976,37(7):993-999.
• [28] Yamada R,Tremmel JA,Tanaka S,et al.Functional versus anatomic assessment of myocardial bridging by intravascular ultrasound:impact of arterial compression on proximal atherosclerotic plaque[J].J Am Heart Assoc,2016,5(4):e001735.
• [29] Tsujita K,Maehara A,Mintz GS,et al.Comparison of angiographic and intravascular ultrasonic detection of myocardial bridging of the left anterior descending coronary artery[J].Am J Cardiol,2008,102(12):1608-1613.
• [30] Otsuka T,Ueki Y,Kawai K,et al.Definition of myocardial bridge by optical coherence tomography:validation by angiography,IVUS,and histology[J].JACC Cardiovasc Imaging,2023,16(5):716-718.
• [31] Escaned J,Cortés J,Flores A,et al.Importance of diastolic fractional flow reserve and dobutamine challenge in physiologic assessment of myocardial bridging[J].J Am Coll Cardiol,2003,42(2):226-233.
• [32] Pargaonkar VS,Kimura T,Kameda R,et al.Invasive assessment of myocardial bridging in patients with angina and no obstructive coronary artery disease[J].EuroIntervention,2021,16(13):1070-1078.
• [33] Tarantini G,Barioli A,Nai Fovino L,et al.Unmasking myocardial bridge-related ischemia by intracoronary functional evaluation[J].Circ Cardiovasc Interv,2018,11(6):e006247.
• [34] Xu B,Tu SX,Qiao SB,et al.Diagnostic accuracy of angiography-based quantitative flow ratio measurements for online assessment of coronary stenosis[J].J Am Coll Cardiol,2017,70(25):3077-3087.
• [35] Qi Q,Liu G,Yuan ZZ,et al.Quantitative flow ratio-guided surgical intervention in symptomatic myocardial bridging[J].Cardiol J,2020,27(6):685-692.
• [36] Tang CX,Liu CY,Lu MJ,et al.CT FFR for ischemia-specific CAD with a new computational fluid dynamics algorithm a Chinese multicenter study[J].JACC Cardiovasc Imaging,2020,13(4):980-990.
• [37] Yu YR,Yu LH,Dai X,et al.CT fractional flow reserve for the diagnosis of myocardial bridging-related ischemia:a study using dynamic CT myocardial perfusion imaging as a reference standard[J].Korean J Radiol,2021,22(12):1964-1973.
• [38] Gawor R,Ku■achcińska A,et al.Myocardial perfusion GSPECT imaging in patients with myocardial bridging[J].J Nucl Cardiol,2011,18(6):1059-1065.
• [39] Xu RD,Yang H,Zhang J,et al.Dynamic perfusion SPECT for functional evaluation in symptomatic patients with myocardial bridging[J].J Nucl Cardiol,2023,30(5):2058-2067.
• [40] Aleksandric SB,Djordjevic-Dikic AD,Dobric MR,et al.Functional assessment of myocardial bridging with conventional and diastolic fractional flow reserve:vasodilator versus inotropic provocation[J].J Am Heart Assoc,2021,10(13):e020597.
• [41] Pargaonkar VS,Rogers IS,Su J,et al.Accuracy of a novel stress echocardiography pattern for myocardial bridging in patients with angina and no obstructive coronary artery disease:a retrospective and prospective cohort study[J].Int J Cardiol,2020,311:107-113.
• [42] Smith AJ,Cromie AMM,Bowles L,et al.Beta blockers and hypertrophic obstructive cardiomyopathy:a systematic review and meta-analysis[J].Open Heart,2025,12(2):e003460.
• [43] Bjerregaard L,Dybro AM,Saaby L,et al.Beta-blocker(bisoprolol)vs calcium-channel blocker(verapamil)in nonobstructive hypertrophic cardiomyopathy a randomized triple-crossover physiologic trial[J].JACC,2026,87(8):1063-1083.
• [44] Olivotto I,Oreziak A,Barriales-Villa R,et al.Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy(EXPLORER-HCM):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2020,396(10253):759-769.
• [45] Chiang M,Sychterz C,Perera V,et al.Physiologically based pharmacokinetic modeling and simulation of mavacamten exposure with drug-drug interactions from CYP inducers and inhibitors by CYP2C19 phenotype[J].Clin Pharmacol Ther,2023,114(4):922-932.
• [46] McGurk KA,Bilgehan N,Ware JS.Pharmacogenetic influences over mavacamten pharmacokinetics:considerations for the treatment of individuals with hypertrophic cardiomyopathy[J].Circulation,2024,149(23):1786-1788.
• [47] Coats CJ,Masri A,Nassif ME,et al.Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy:Results From SEQUOIA-HCM[J].J Am Heart Assoc,2024,13(15):e035993.
• [48] Kan J,Ge Z,Zhang JJ,et al.Incidence and clinical outcomes of stent fractures on the basis of 6,555 patients and 16,482 drug-eluting stents from 4 centers[J].JACC Cardiovasc Interv,2016,9(11):1115-1123.
• [49] Jiang QX,Liang C,Wu ZG.Myocardial bridging is a potential risk factor of very late stent thrombosis of drug eluting stent[J].Med Sci Monit,2012,18(5):HY9-HY12.
• [50] 中国研究型医院学会《冠状动脉心肌桥诊断与治疗专家共识》专家组.冠状动脉心肌桥诊断与治疗的专家共识[J].中国研究型医院，2022,9(5):1-8.
• [51] 国家心血管病专家委员会心力衰竭专业委员会，中国医师协会心力衰竭专业委员会，中华医学会心血管分会心力衰竭学组，等.中国肥厚型心肌病指南2022[J].中华心力衰竭和心肌病杂志，2022,6(2):80-105.
• [52] Hemmati P,Schaff HV,Dearani JA,et al.Clinical outcomes of surgical unroofing of myocardial bridging in symptomatic patients[J].Ann Thorac Surg,2020,109(2):452-457.
• [53] Corban MT,Hung OY,Eshtehardi P,et al.Myocardial bridging contemporary understanding of pathophysiology with implications for diagnostic and therapeutic strategies[J].J Am Coll Cardiol,2014,63(22):2346-2355.
• [54] Xu XR,Zhang MK,Wu QY,et al.Surgical intervention of myocardial bridge combined coronary artery disease:could a combination of supra-arterial myotomy and CABG be a better option?[J].J Cardiothorac Surg,2023,18(1):123.
• [55] Kunkala MR,Schaff HV,Burkhart H,et al.Outcome of repair of myocardial bridging at the time of septal myectomy[J].Ann Thorac Surg,2014,97(1):118-123.
• [56] Wang SW,Wang SY,Lai YQ,et al.Midterm results of different treatment methods for myocardial bridging in patients after septal myectomy[J].J Card Surg,2021,36(2):501-508.
• [57] 于建波，王生伟，来永强.肥厚型梗阻性心肌病合并冠状动脉病变的外科处理[J].心肺血管病杂志，2021,40(7):707-710.
• [58] Fang J,Liu YN,Zhu Y,et al.First-in-human transapical beating-heart septal myectomy in patients with hypertrophic obstructive cardiomyopathy[J].J Am Coll Cardiol,2023,82(7):575-586.
• [59] Fang J,Chen Y,Liu YN,et al.Transapical beating-heart septal myectomy for obstructive hypertrophic cardiomyopathy:lessons learned after the learning curve period[J].Circ Cardiovasc Interv,2025,18(5):e015044.